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The receptor for epidermal growth factor (EGF) is a transmem-
brane glycoprotein with intrinsic tyrosine kinase activity (Ullrich
and Schlessinger, 1990). Many human cancers of epithelial origin
express high numbers of EGF receptors and are stimulated by acti-
vation of the receptor via a transforming growth factor-a (TGF-
a)/EGF receptor autocrine loop (Ozanne et al, 1986; Cowley et al,
1986; Ishitoya et al, 1989; Hendler and Ozanne, 1984). The
increased receptor levels are associated with poor clinical prog-
nosis in patients with cancers of the bladder (Neal et al, 1985),
breast (Sainsbury et al, 1985), and lung (Veale et al, 1987) and
others. Blockade of EGF receptor as an approach for anticancer
therapy has been extensively studied over the past decade (Fan and
Mendelsohn, 1998).
Monoclonal antibody (mAb) 225 binds to EGF receptor with an
affinity similar to that of the natural ligands EGF and TGF-a,
competes with these natural ligands for receptor binding, and
inhibits ligand-induced activation of the receptor tyrosine kinase
(Sato et al, 1983; Gill et al, 1984). This antibody, along with other
EGF receptor-blocking mAbs, inhibits the proliferation of a
variety of cultured and xenografted tumour cell lines that are stim-
ulated by the TGF-a/EGF receptor autocrine loop, including cell
lines derived from cancers of the vulva (Fan et al, 1993a; 1994),
breast (Ennis et al, 1989), prostate (Peng et al, 1996; Hofer et al,
1991), ovary (Ye et al, 1999), bladder (Perrotte et al, 1999), kidney
(Prewett et al, 1998), lung (Lee et al, 1992), colon (Karnes et al,
1992; Wu et al, 1996), brain (Wersall et al, 1997), and head and
neck (Modjtahedi et al, 1993). It has been postulated that these
antibodies inhibit tumour cell proliferation by an antibody-medi-
ated interruption of the autocrine activation of EGF receptors in
cancer cells (Van de Vijver et al, 1991; Fan et al, 1993b; Baselga et
al, 1996). The antibody-mediated growth inhibition in most malig-
nant cell lines has been attributed primarily to a reduced prolifera-
tion rate with an increased cell population in G1 phase of the cell
cycle (Fan et al, 1997; Wu et al, 1996; Peng et al, 1996). In nonma-
lignant epithelial cells there was a prominent cytostatic effect with
complete G1 arrest (Stampfer et al, 1993; Chou et al, 1999).
DiFi colon cancer cells are unique in that exposure of these cells
to mAb 225 resulted in not only G1 phase arrest of cell cycle, with
a concomitant increase in the level of p27Kip1 and a decrease in
CDK activity, but also subsequent cell death through apoptosis
(Wu et al, 1995; 1996). When nude mice bearing well-established
subcutaneous DiFi cell xenografts were treated with mAb 225, the
tumour was completely eradicated, a result not normally seen with
other cancer cells stimulated by the TGF-a/EGF receptor
autocrine pathway (Masui et al, 1991). The EGF receptor gene in
these cells was not found to be rearranged or genetically altered,
but the gene was found to be amplified in the range of 60–80
copies per cell, which is approximately twice the copy number
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DiFi cell cultures in log-phase growth secrete measurable amounts
of TGF-a (347 pg per 106 cells per 24 h) into their culture medium
and have approximately 4.8 ´ 106 receptors per cell (Gross et al,
1991; Untawale et al, 1993). Although the apoptosis induced by
the anti-EGF receptor mAb 225 is well documented, it is not
known whether mAb 225 induces apoptosis by specifically
blocking EGF receptor function or whether the apoptosis results
from an incidental cross-reaction of mAb 225 with an unidentified
cell surface protein, binding of which by mAb 225 can trigger an
apoptotic pathway in DiFi cells. Additionally, the intracellular
biochemical pathways by which mAb 225 induces apoptosis are
still poorly understood.
Caspases are a family of cysteinyl aspartate-specific proteinases
that mediate highly specific proteolytic cleavage events in dying
cells. Although caspase-independent apoptosis may exist (Xiang
et al, 1996; Susin et al, 1999), several lines of evidence indicate
that caspases are critical for apoptosis in most cases. Caspase acti-
vation correlates with the onset of apoptosis, and caspase inhibi-
tion attenuates apoptosis (Bump et al, 1995; Cohen, 1997; Tewari
et al, 1995). C. elegans mutants lacking the worm caspase CED-3
have a complete absence of developmental programmed cell death
(Ellis and Horvitz, 1986). Animals deficient in caspase-3, -8 or -9
die perinatally because of profound defects in developmental
programmed cell death (Green, 1998). Targeted deletion of
caspase genes has shown a definitive role for caspase in apoptosis
and inflammation (Green, 1998). To understand the mechanism by
which mAb 225 induces apoptosis, it is essential to explore
whether and how the caspase cascade is involved in the antibody-
induced apoptosis.
In the current study, we examined a panel of four different
mAbs (14E1, 108, 528 and 225) directed against individually
distinct epitopes on the EGF receptors for their effects on inducing
apoptosis. We found that each of the mAbs induced apoptosis in
DiFi cells. We further demonstrated the involvement of caspases-
3, -8 and -9 in mAb 225-induced apoptosis. Because mAb 225
binds to and blocks EGF receptor function and because activation
of the c-jun N-terminal kinase-1 (JNK1) pathway with a concomi-
tant repression of the MAP kinase cascade may result in apoptosis
under certain circumstances, we therefore also investigated
whether the JNK1 signaling pathway was involved in mAb 225-
mediated activation of the caspase cascade and apoptosis in DiFi
cells. We found that, while ultraviolet (UV) irradiation of DiFi
cells strongly activated JNK1 and subsequently activated the
caspase cascade and induced apoptosis, exposure of DiFi cells to
mAb 225 did not activate JNK1.
MATERIALS AND METHODS
Materials
Anti-EGF receptor mAbs 225, 528, 108, and anti-HER2 mAb 4D5
(which we used as a control) were previously described (Fan et al,
1993c; Ye et al, 1999). Anti-EGF receptor mAb 14E1 was kindly
provided by the Ernst Schering Research Foundation (Berlin,
Germany). Anti-poly (ADP-ribose) polymerase (PARP) mAb
(clone C-2–10) was purchased from CHUL Research Center,
Laval University (Quebec, Canada). Anti-caspase-3 mAb (clone
19) was obtained from Transduction Laboratories (Lexington, KY,
USA). Anti-JNK1 mAb (clone G151–333) was purchased from
PharMingen (San Diego, CA, USA). DEVD-CHO and z-VAD-
fmk were obtained from CalBiochem Corp. (San Diego, CA,
USA). Caspase-3 substrate Ac-DEVD-pNA, caspase-8 substrate
Ac-IETD-pNA, and caspase-9 substrate Ac-LEHD-pNA were
from Alexis Corp. (San Diego, CA, USA). Protein A-Sepharose
beads used for immunoprecipitation were purchased from
Repligen Corp. (Cambridge, MA, USA). All other reagents were
purchased from Sigma Chemical (St. Louis, MO, USA) unless
otherwise specified.
Cells and tissue culture
DiFi human colorectal adenocarcinoma cells were described
previously (Wu et al, 1995; 1996). The cells were maintained in a
mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-12
medium (1:1, v/v) supplemented with 10% fetal bovine serum
(FBS) in a 37°C humidified atmosphere containing 95% air and
5% CO2 and were split twice a week.
Clonogenic assay
DiFi cells were seeded into 60 mm dishes at a density of 1000 cells
per dish in 5 ml of medium containing 10% FBS and cultured for
15 days in a 37°C humidified atmosphere containing 95% air and
5% CO2. The cell clones were stained for 5 min with a solution
containing 0.5% crystal violet and 25% methanol, followed by
three rinses with tap water to remove excess dye.
Analysis of DNA fragmentation
Cells (approximately 1 ´ 106) were lysed with 200 ml of lysis
buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 0.5% N-lauroyl sarco-
sine, and 0.5 mg ml–1 proteinase K). The lysates were then incu-
bated in a 50°C water bath for 1 h prior to the addition of
heat-boiled RNase A to the final concentration of 0.5 mg ml–1; the
lysates were then incubated for an additional hour in the 50°C
water bath. After the digestion, the samples were diluted with an
equal volume of TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA).
DNA was extracted three times with phenol-chloroform-isoamyl
alcohol (25:24:1, v/v/v) and precipitated with 0.2 ´ volume of 3 M
ammonia acetate and 2 ´ volumes of ethyl alcohol. The DNA
precipitates were dissolved in TE buffer, and 5 mg of DNA from
each sample was analyzed by 1.5% agarose gel electrophoresis.
Quantification of apoptosis by ELISA
We used an apoptosis ELISA kit (Roche Diagnostics Corp., IN,
USA) to quantitatively measure cytoplasmic histone-associated
DNA fragments (mononucleosomes and oligonucleosomes) after
induced cell death. This photomeric enzyme immunoassay was
performed exactly according to the manufacturer’s instructions.
Scanning and transmission electron microscopy
DiFi cells were rinsed in serum-free medium to remove unbound
protein and were then treated with a fixative containing 3%
glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate
buffer, pH 7.3 (Ted Pella, Inc., Redding, CA, USA) for 1 h at
ambient temperature. After fixation, the cells were washed three
times with 0.1 M Millipore-filtered cacodylate-buffered tannic
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osmium tetroxide (Electron Microscopy Sciences, Ft. Washington,
PA, USA) for 1 h. The samples were prepared by standard proce-
dures and examined in a Hitachi S-520 scanning electron micro-
scope at an acceleration voltage of 5 kV and in a JEOL 1200-EX
transmission electron microscope at an acceleration voltage 
of 80 kV.
Caspase enzymatic activity assay
Caspase enzymatic activities were measured by colourimetric
assays with a kit purchased from Clontech Laboratories, Inc. (Palo
Alto, CA, USA). The assay is based on spectrophotometric detec-
tion of the chromophore p-nitroanilide (pNA), which is cleaved
from caspase-specific substrates by activated caspases (DEVD-
pNA by activated caspase-3, IETD-pNA by activated caspase-8,
and LEHD-pNA by activated caspase-9). The assay was
performed exactly according to the manufacturer’s instructions.
Terminal deoxynucleotidyl transferase-mediated 
dUTP-X nick end labelling (TUNEL) assay
DiFi cells were harvested and fixed in 2% formaldehyde on ice for
15 min; the fixing solution was then removed and the cell pellets
were washed once with PBS. Subsequently, the cells were post-
fixed in ice-cold 70% ethanol for 30 min, followed by washing the
cells once with PBS and incubating the cells in 50 ml of terminal
deoxynucleotidyl transferase (TdT) reaction solution containing 5
units of TdT, 0.5 nmol of biotin-dUTP, and 2.5 mM CoCl2 in TdT
buffer (purchased from Roche Diagnostics Corp.) at 37°C for 1 h.
After the reaction, the cells were stained with a buffer containing
2.5 mg ml–1 FITC-avidin, 0.1% Triton X-100, 5% dried low-fat
milk in 4 ´ SSC (0.6 M sodium chloride, 60 mM sodium citrate,
pH 7) in the dark at room temperature for 1 h. Before flow cyto-
metric analysis with a FACScan flow cytometer (Becton
Dickinson, San Jose, CA, USA), the cells were counterstained
with a solution containing 5 mg ml–1 propidium iodide and 
10 mg ml–1 RNase A in PBS. The FITC signal was analysed with
Epics Elite software (Coulter Corp., Miami, FL, USA).
Western blot analysis
Equal amounts of protein were used for western blot analysis with
the indicated antibodies. Briefly, cells were lysed in a lysis buffer
containing 50 mM Tris, pH 7.4, 50 mM NaCl, 0.5% NP-40, 
50 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluo-
ride, 25 mg ml–1 leupeptin, and 25 mg ml–1 aprotinin. The lysates
were centrifuged at the full speed of a microcentrifuge for 15 min
and the supernatants were collected for protein concentration
determination, SDS-PAGE, and western blot analysis with specific
antibodies as described in the figure legends.
Purification of GST-c-jun fusion protein
DH5a bacteria transformed with plasmid pGEX-c-jun (kindly
provided by Dr B Su at The University of Texas MD Anderson
Cancer Center, Houston, TX, USA) were grown in LB medium.
After induction with 0.1 mM isopropyl-b-D-thiogalactopyrano-
side (IPTG) for 2 h, the bacteria were harvested and resus-
pended in EBC lysis buffer (20 mM Tris, pH 7.4, 50 mM NaCl,
0.5% NP-40, 1% Triton X-100) containing 0.1 mg ml–1 leupeptin,
0.04 U ml–1 aprotinin, and 1 mM phenylmethylsulphonyl fluoride.
The bacteria were sonicated three times at 4°C for 10 s each time
and then centrifuged at the full speed of a microcentrifuge at 4°C
for 5 min. The supernatants were transferred to a new tube with the
addition of 100 ml of 50% glutathione sepharose 4B slurry
(Pharmacia Biochech Inc., Piscataway, NJ, USA). The mixture
was incubated on a rotator at 4°C for 2 h, and the Sepharose 4B
beads were then collected by half-full speed microcentrifugation
for 15–30 s and then washed with EBC lysis buffer three times.
The GST-c-jun fusion protein was eluted by an elution buffer 
(10 mM glutathione, 50 mM Tris, pH 8.0) and stored at –80°C 
in aliquots.
JNK1 kinase assay
Cells were lysed with a buffer containing 50 mM Tris, pH 7.4, 
50 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl fluoride, 25 mg ml–1 leupeptin, and 25 mg
ml–1 aprotinin. JNK1 was immunoprecipitated from 50 mg of
lysate with 1 mg of specific anti-JNK1 mAb (clone G151–333) at
4°C for 3 h and with a 20 ml bed volume of protein A-Sepharose
for another 3 h. The immunoprecipitates were washed three times
with the lysis buffer and twice with a kinase buffer (20 mM Tris,
7.5 mM MgCl2, 1 mM dithiothreitol). The kinase reaction was
performed by incubating the immunoprecipitates with 40 ml of
kinase buffer containing 2 mg of GST-c-jun, 25 mM lithium ATP,
and 5 mCi of [g-32P]ATP (New England Nuclear, Boston, MA,
USA) at 30°C for 30 min. The reaction was terminated by boiling
the samples with 40 ml of 2 ´ SDS sample buffer. The products of
the reaction were resolved using 10% SDS-PAGE and subjected to
autoradiography.
RESULTS
Apoptosis induced by mAbs directed against the EGF
receptors and its characteristics
In 1995, we first reported that exposure of DiFi cells to mAb 225
resulted in cell death through apoptosis (Wu et al, 1995). To
further explore the generality of the apoptosis induced by anti-
EGF receptor antibodies, we examined the effects of a panel of
four different anti-EGF receptor mAbs (14E1, 108, 528 and 225)
on the induction of apoptosis in DiFi cells. These antibodies bind
to individually distinct epitopes on the extracellular domain of the
EGF receptor and block the binding of natural ligands to the
receptor (Fan et al, 1993c; Schmidt et al, 1997). As a control, we
used the mAb 4D5 (Herceptin), which is directed against the extra-
cellular domain of HER-2, a structurally similar receptor of the
EGF receptor superfamily. Cell death was observed 24 h after the
cells were exposed to these antibodies in medium containing 0.5%
FBS. Treated and untreated cells were lysed, and chromosomal
DNA was prepared for agarose gel electrophoresis analysis to
demonstrate the characteristic DNA fragmentation (ladder) (Wu et
al, 1995). We found that exposure of the DiFi cells to any of the
four anti-EGF receptor mAbs produced a characteristic DNA
ladder, which was not observed in the untreated cells or in cells
treated with the anti-HER-2 mAb 4D5 (Figure 1A).
We further characterized the mAb dose- and time-dependency
of mAb 225-induced apoptosis. The mAb 225-induced apoptosis
mAb 225-induced apoptosis and caspase activation 1993
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dose determined by DNA fragmentation electrophoresis analysis
was greater than 5 nM of mAb 225. However, the dose required to
induce apoptosis was lower (1–2 nM) with a more sensitive apop-
tosis ELISA analysis (data not shown). DNA fragmentation was
first detectable approximately 12 h after continuous exposure of
the cells to 20 nM mAb 225 (Figure 1C). However, a 1 h exposure
of the cells to 20 nM mAb 225 was sufficient to induce apoptosis
that was measured 24 h later (Figure 1D). The percentage of the
cells that were apoptotic at 24 h after 1 h of incubation with mAb
225 was approximately 25–30% by Hoechst (#33258) dye
staining. This result was similar to the percentage of the cells that
were apoptotic after being continuously exposed to mAb 225 for
24 h (data not shown).
A caveat is that the dose-dependent induction of DNA fragmen-
tation by mAb 225 in Figure 1B does not necessarily reflect a
similar pattern of end-point of cell survival. The clonogenic
survival shown in Figure 2 indicates that, in a 15-d culture period,
there were no differences in clone survival of the cells exposed to
the serial concentrations of mAb 225 that were used in Figure 1B.
The mAb 225-induced apoptosis in DiFi cells was characterized
with typical morphological changes in the cell membrane, the
nuclei, and the mitochondria. Scanning electron micrography
shows that untreated DiFi cells displayed features typical of colon
epithelial cells, i.e. an abundance of delicate microvilli that were
orderly and closely packed on the cell surface, whereas mAb 225-
treated cells exhibited volume shrinkage, distortion of cell surface
microvilli, and the appearance of elongated membrane blebbings
(Figure 3A). Transmission electron micrography showed that
untreated cells contained intact nuclei and mitochondria filled with
integral cristae whereas the antibody-treated cells developed frag-
mented nuclei, membrane-wrapped apoptotic bodies, and swollen
mitochondria (Figure 3B and 3C).
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Figure 1 Induction of DNA fragmentation by anti-EGF receptor mAbs in
DiFi cells. (A) DiFi cells were exposed to 20 nM anti-HER2 mAb 4D5 or to 
20 nM each of anti-EGF receptor mAb 14E1, 108, 528, or 225 in 0.5% FBS
medium for 24 h. The cells were harvested, and the chromosomal DNA was
extracted and subjected to agarose gel electrophoresis. (B) DiFi cells were
exposed to increasing concentrations of mAb 225 for 24 h, and the cells were
lysed for DNA agarose gel electrophoresis analysis. (C) DiFi cells were
exposed to 20 nM mAb 225 for the indicated times, and the cells were lysed
at each time point for DNA agarose gel electrophoresis analysis. (D) DiFi
cells were exposed to 20 nM mAb 225 for the indicated times and were
cultured for additional time in mAb 225-free medium for a total of 24 h. The
cells were lysed for DNA agarose gel electrophoresis analysis. Both adherent
and floating cells were harvested for DNA extraction and agarose gel
analysis as described in Materials and methods.
Figure 3 Characteristic morphological changes in the cell membrane,
nucleus, and mitochondria of DiFi cells following mAb 225 treatment. DiFi
cells were incubated in 0.5% FBS medium containing 20 nM mAb 225 for 
24 h; controls were similarly incubated without mAb 225. The cells were 
then harvested, fixed, and examined by scanning electron microscopy and
transmission electron microscopy as described in Materials and methods.
Magnified ´5000.
Figure 2 Clonogenic survival of DiFi cells following treatment with anti-EGF
receptor mAb 225. The cells were seeded as described in Materials and
methods. On the next day, the cells were exposed to the indicated
concentrations of mAb 225 and cultured in a 37°C incubator with 95% air and
5% CO2 for 15 days. The cell clones were stained with crystal violet blue.Role of the execution caspase-3 in mAb 225-induced
apoptosis
Caspase-3 is a major execution caspase required for the character-
istic DNA fragmentation (Figure 1) and morphological changes
(Figure 3) associated with apoptosis (Janicke et al, 1998a). To
demonstrate whether treatment of DiFi cells with mAb 225 trig-
gers a cascade that results in activation of caspase-3, we measured
the enzyme activity of caspase-3 following exposure of DiFi cells
to mAb 225. We found a time-dependent activation of caspase-3,
which was detectable between 8 h and 16 h after exposure of 
DiFi cells to mAb 225 (Figure 4A). This activation of caspase-3
coincided with cleavage of the 116-kDa PARP, one of well-
documented substrates for activated caspase-3 (Figure 4B). The
appearance of a characteristic 85-kDa PARP fragment was
observed temporally with activation of caspase-3, as shown by the
reduced level of the 32-kDa proenzyme due to its cleavage by its
upstream caspases. Our results suggest that the apoptosis induced
by mAb 225 in DiFi cells involves the caspase-3 activity.
We further explored whether there was a causal correlation of
caspase-3 activation and mAb 225-induced PARP cleavage by
selectively blocking caspase-3 activity with specific synthetic
peptide inhibitors. When DiFi cells were exposed to the caspase-3
specific inhibitor DEVD-CHO, the caspase-3 activity was
markedly inhibited 24 h after exposure of cells to mAb 225 (Figure
4C). Inhibition of caspase-3 with DEVD-CHO partially reduced
the rate of PARP cleavage after mAb 225 treatment. Cleavage of
PARP was detected as early as 8 h after treatment with mAb 225
alone (Figure 4D, lanes 2 and 3), but when the cells were pre-incu-
bated with DEVD-CHO the cleavage was not detected until 24 h
after treatment (Figure 4D, lanes 4 and 5). Pre-incubation of the
cells with a pan-caspase inhibitor, z-VAD-fmk, more strongly
prevented cleavage of PARP by mAb 225 than did DEVD-CHO
(Figure 4D, lanes 6 and 7). Compared with the results of mAb 225
treatment alone, the cells pre-incubated with DEVD-CHO or z-
VAD-fmk retained relatively higher levels of the 116-kDa PARP at
both the 8 h and 24 h time-points (Figure 4D, lane 2 compared
with lanes 4 and 6, and lane 3 compared with lanes 5 and 7, respec-
tively), especially when the pan-caspase inhibitor z-VAD-fmk was
used.
We accordingly evaluated the effects of these caspase inhibitors
on mAb 225-induced apoptosis. TUNEL assay showed that,
compared with results for mAb 225 treatment alone, the relative
percentage of apoptotic cells (FITC-positive cells) was lower in
the cells pre-treated with DEVD-CHO or z-VAD-fmk 12 h before
the cells were exposed to mAb 225 (Figure 5A), and this result was
also consistent with the PARP cleavage analysis indicating that z-
VAD-fmk was a stronger inhibitor than DEVD-CHO in preventing
mAb 225-induced PARP cleavage and apoptosis (Figure 5B). The
FITC-positive rates varied from 10–30% of total cells in several
repeated experiments in our study, depending upon the intensity of
FITC that was conjugated to the avidin used in the TUNEL assay.
However, in each experiment, the relative fold increase of the
FITC-positive rate in mAb 225-treated cells over that in untreated
cells was consistent (Figure 5A). Parallel experiments analysed by
chromosomal DNA agarose gel electrophoresis had similar results
(Figure 5B). In these experiments, the pan-caspase inhibitor z-
VAD-fmk more strongly inhibited mAb 225-induced apoptosis
than did DEVD-CHO. These results indicated that activation of
caspase-3 is a major step in mAb 225-induced apoptosis but also
that caspase-3 may not be the only caspase contributing to the
apoptosis.
Activation of the initiation caspase-8 and caspase-9 in
mAb 225-induced apoptosis
We measured the specific activities of the initiation caspases-8 and
-9 following exposure of DiFi cells to mAb 225. We found a time-
dependent activation of caspase-8, which was detectable between
8 h and 16 h after exposure of the cells to mAb 225 (Figure 6A).
There was also an activation of caspase-9, which lagged a few
hours behind the activation of caspase-8. These results indicate
that both the caspase-8-initiated and the caspase-9-initiated
caspase cascades are activated in the apoptosis induced by mAb
mAb 225-induced apoptosis and caspase activation 1995
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Figure 4 Activation of caspase-3 and cleavage of PARP by mAb 225. 
(A) DiFi cells were exposed to 20 nM 225 for the indicated times. Cell lysates
were prepared and subjected to an enzymatic assay for the activity of
caspase-3 as described in Materials and methods. (B) An equal amount of
protein for each sample in (A) was resolved by 8% SDS electrophoresis,
followed by Western blot analysis with specific antibodies directed against
PARP, caspase-3/CPP32, or b-actin. (C) DiFi cells were exposed to 20 nM
mAb 225 with and without pre-incubation of the cells with 10 mM DEVD-CHO
for 12 h. Cell lysates were then prepared and subjected to an enzymatic
assay for caspase-3 activity. (D) Inhibition of mAb 225-induced PARP
cleavage by caspase inhibitors. DiFi cells were pre-incubated with either 
10 mM DEVD-CHO (DEVD) or 100 mM z-VAD-fmk (VAD) for 12 h. The cells
were harvested 8 and 24 h after mAb 225 was added to the culture and then
subjected to Western blot analysis with a specific antibody directed against
PARP or b-actin.
Figure 5 Inhibition of mAb 255-induced apoptosis by caspase inhibitors.
DiFi cells were pre-incubated with either 10 mM DEVD-CHO or 100 mM z-
VAD-fmk for 12 h and then incubated with 20 nM mAb 225 for another 24 h.
Both adherent and floating cells were collected and subjected to a TUNEL
assay (A) and to a chromosomal DNA agarose gel electrophoresis assay
(B).225 in these cells. UV irradiation of DiFi cells for 40 s also acti-
vated the initiation caspases-8 and -9 (Figure 6B) and the execu-
tion caspase-3 (data not shown). However, compared with the
kinetics of the caspase cascade activation by mAb 225, which
showed relative delayed but steady increases in the caspase activi-
ties over 24 h, the activation of caspase-8 and caspase-9 by UV
was detected 4 h shortly after the treatment and reached a plateau
afterward.
Lack of involvement of the JNK signalling pathway in
mAb 225-induced apoptosis
Recent study has suggested possible interactions, under certain
circumstances, between the JNKs pathway and the caspase
cascade during apoptosis (Lei et al, 1998; Muhlenbeck et al, 1998;
Shiah et al, 1999). JNKs participate in cellular responses to envi-
ronmental stresses, apoptotic agents, and even some mitogenic
stimuli (Chen et al, 1996). To investigate possible involvement of
the JNK signaling pathway in mAb 225-induced apoptosis and
activation of the caspase cascade in DiFi cells, we examined the
JNK1 kinase activity when DiFi cells were exposed to mAb 225.
Exposure of DiFi cells to either mAb 225 or UV irradiation
induced apoptosis (Figure 7A and 7B). However, only the UV irra-
diation activated JNK1 kinase (Figure 7C). The levels of JNK1
protein remained unchanged during the exposure period to mAb
225 or UV irradiation. This result indicated that the JNK1
signaling pathway is competent in DiFi cells but that it is not
involved in mAb 225-induced apoptosis in DiFi cells.
DISCUSSION
A human-mouse chimeric version of mAb 225 (C225) is currently
being evaluated in clinical trials of its antitumour activity against
human cancers of the pancreas, colon, and head and neck.
Ongoing studies are investigating a potential synergy between the
anti-EGF receptor mAb 225-mediated disruption of EGF receptor
function and conventional chemotherapy or radiation therapy
(Baselga et al, 2000; Perez-Soler et al, 1998; Mendelsohn et al,
1999). Because a direct and targeted approach to cancer therapy is
preferable, demonstration of the mechanism by which mAb 225
induces apoptosis specifically in DiFi colorectal cancer cells may
direct us to develop new therapeutic strategies that will maximize
the antitumour activity of mAb 225 by inducing programmed cell
death in a broad range of human cancers without requiring combi-
nation treatment with conventional chemotherapy or radiation
therapy.
In the present study, we demonstrated that apoptosis was in-
duced by several different mAbs that recognize individual distinct
epitopes on the EGF receptors on DiFi cells. This result makes it
unlikely that mAb 225 induces apoptosis by cross-reacting with an
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Figure 6 Activation of caspase-8 and caspase-9 by mAb 225 and UV
irradiation in DiFi cells. DiFi cells were exposed to 20 nM mAb 225 for the
indicated time periods (A) or were UV-irradiated for 40 s, followed by regular
culture for the indicated time periods (B). Cell lysates were prepared and
subjected to enzymatic assays for the activities of caspase-8 and caspase-9
as described in Materials and methods.
Figure 7 Activation of JNK in UV irradiation-induced apoptosis but not in
mAb 225-induced apoptosis in DiFi cells. (A) and (B) DiFi cells were exposed
to 20 nM mAb 225 for the indicated time periods (A) or were UV-irradiated for
40 s, followed by regular culture for the indicated time periods (B). Cell lysate
were prepared for an apoptosis ELISA as described in Materials and
methods. (C) DiFi cells were treated as described in (A) and (B) and then
harvested for JNK1 kinase activity analysis with an in vitro assay using GST-
Jun as a substrate and for western blot analysis with antibodies directed
against JNK1. The bar graph underneath was obtained by phosphoimaging
analysis of GST-c-jun phosphorylation by JNK1.unidentified ‘death’ protein rather than the EGF receptor on DiFi
cell surfaces. The commitment of DiFi cells to apoptosis shortly
after 1 h of exposure to mAb 225 sharply contrasts with the anti-
proliferative activity of mAb 225 in many other cell lines, which
normally requires over 24 h of continuous exposure of the cells to
the antibody to arrest cell cycle progression, suggesting that the
apoptotic activity of anti-EGF receptor mAb in DiFi cells may not
be directly associated with the anti-proliferative effect of mAb 225
on many other cell lines. We also demonstrated that caspases-3, -8
and -9 are activated during mAb 225-induced apoptosis and the
latter apoptosis differs from the apoptosis of DiFi cells induced by
UV irradiation in that it does not involve JNK1 activity. In other
studies, JNK1 activity was associated with activation of caspases
by several anticancer drugs (Seimiya et al, 1997; Shiah et al,
1999). In our study, the JNK1 activity was temporally associated
with the activation of caspases-3, -8 and -9 during UV irradiation-
induced apoptosis, suggesting a competent JNK signalling
pathway in DiFi cells during the apoptosis. However, this was not
the case in the activation of the caspase cascade during mAb 225-
induced apoptosis in these cells.
An understanding of caspase regulation is intimately linked to
the ability of researchers to rationally manipulate apoptosis for
therapeutic application to human cancer. Caspases are constitu-
tively expressed as latent proenzymes in living cells. Two initia-
tion pathways of caspase cascade during apoptosis have been
described (Thornberry and Lazebnik, 1998; Ashkenazi and Dixit,
1998; Green and Reed, 1998; Sun et al, 1999). The first pathway is
the caspase-8 initiated apoptosis induced by death receptors, such
as Fas or tumour necrosis factor (TNF) receptors (Boldin et al,
1996; Muzio et al, 1996; 1998; Yang et al, 1998); the second
pathway involves the complex of cytochrome c, Apaf-1 and
caspase-9 following stimulation of the cells with diverse proapop-
totic signals that converge at the mitochondrial level and provoke
the translocation of cytochrome c from the mitochondria to the
cytoplasm (Kluck et al, 1997; Adachi et al, 1997; Kharbanda et al,
1997; Kim et al, 1997; Bossy-Wetzel et al, 1998). The character-
istic induction of apoptosis by anti-EGF receptor mAb is reminis-
cent of the apoptosis induced by anti-fas/CD95 mAb (Itoh et al,
1991). We examined the possible involvement of the fas-mediated
apoptotic pathway in mAb 225-induced apoptosis. Exposure of
DiFi cells to an anti-fas mAb did not trigger apoptosis, suggesting
that DiFi cells do not constitutively express functional fas (data not
shown). The apoptosis induced by the anti-EGF receptor mAb has
so far been observed only in DiFi colon cancer cells. In most
tumour cell lines studied, blockade of the EGF receptor with mAb
has resulted in cell cycle arrest rather than cell death. Two possible
mechanisms by which anti-EGF receptor mAbs induce apoptosis
are being considered. The first possibility is that the DiFi cells may
be genetically defective in certain components that normally
inhibit induction of apoptosis upon EGF receptor blockade.
Alternatively, the EGF receptor in DiFi cells may link to mole-
cule(s) that have apoptosis-triggering activity, and binding of the
receptor by mAb may result in a release or activation of such
molecule(s). Both caspase-8 and caspase-9 may initiate caspase
cascade and thereby induce apoptosis, however, we speculate that
the observed activation of caspase-9 in DiFi cells after mAb 225
treatment could be a consequence of mAb 225-induced activation
of caspase-8 through a mechanism similar to fas-mediated activa-
tion of caspase-8 and caspase-9. Caspase-8 activated by fas path-
way can cleave Bid (a BH3 domain-containing proapoptotic Bcl-2
family member), and the truncated Bid will then translocate to the
mitochondria and induce the release of cytochrome c and subse-
quent activation of caspase-9 (Li et al, 1998). Our data showing
that the kinetics of caspase-9 activation lagged a few hours behind
the activation of caspase-8 support this speculation (Figure 6).
Among the known execution caspases (caspase-3, -6 and -7,
etc), caspase-3 is the major caspase. Induction of apoptosis in
caspase-3-defective MCF-7 human breast cancer cells was accom-
panied by cleavage of PARP, Rb, and DNA-PK without concurrent
appearance of the characteristic DNA internucleosomal degrada-
tion and the characteristic morphological changes associated with
apoptosis; however, introduction of caspase-3 cDNA into the
MCF-7 cells restored a-fodrin cleavage and membrane blebbing
(Janicke et al, 1998a; 1998b). The characteristic induction of DNA
laddering and membrane blebbing in DiFi cells that we observed
following treatment with mAb 225 (Figures 1 and 3) led us to
examine the involvement of caspase-3 in mAb 225-induced
apoptosis in DiFi cells. Our data indicate that caspase-3 is a major
caspase contributing to apoptosis in DiFi cells. In addition, this
pathway also involves activation of caspase-8 and caspase-9.
Inhibition of caspase-3 and pan-caspase activities by specific
inhibitors strongly reduced induction of the apoptosis with
concomitant inhibition of PARP cleavage and DNA fragmentation.
Caspases contribute to apoptosis in a tissue- or cell type-specific
or death signal-specific manner. Caspase-3-disrupted cells that
were highly resistant to apoptosis induced by UV irradiation or
osmotic shock were still sensitive to apoptosis induced by g-irradi-
ation or heat shocks (Woo et al, 1998). The demonstration of the
involvement of the caspase cascade (the initiation caspases-8 and 
-9 and the execution caspase-3) in mAb 225-induced apoptosis
provides important insights for us to further pursue the mecha-
nism.
In summary, we demonstrated that apoptosis could be induced
in DiFi colon cancer cells by a variety of anti-EGF receptor mAbs
that bind to different epitopes on the receptor. This apoptosis is
characterized by classical DNA internucleosomal degradation and
typical caspase-mediated morphological changes, and this apop-
tosis involves activation of caspase-8- and caspase-9-initiated
caspase cascade. We are currently investigating the biochemical
pathway(s) by which mAb 225 induces activation of the caspase
cascade, thereby triggering apoptosis.
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